神经科学与神经精神疾病领域的中美资助布局研究

Funding Layout in Neuroscience and Neuropsychiatric Disorders of China and the US

通过对美国NIH和NSF、我国NSFC、“973计划”和国家重点研发计划在神经科学、神经疾病、精神疾病领域所资助研究项目进行分析,探索两国的研究布局与发展,发现美国在2009、2010年的ARRA政策及2013—2017年的BRAIN计划之后,显著提高了该领域的投入,重点资助神经科学基础研究和技术开发,疾病领域则主要关注神经退行性疾病、抑郁症、精神分裂症和自闭症。我国在该领域的资助力度自“十二五”规划以来得到大力提升,对神经疾病的投入均远高于精神疾病和神经科学,在中风等脑血管疾病领域资助力度最大,神经科学基础技术的开发等主要布局于“973计划”和国家重点研发计划中。

Through the analysis of research projects funded by the US National Institutes of Health (NIH), National Nature Science Foundation of China (NSFC),“973 program” and national key R&D programs in the fields of neuroscience, neurological disorders and mental health/diseases, the research layout and development of the two countries are explored. It is discovered that in the US, NIH significantly increased its investment in this area following the ARRA policy of 2009 and 2010, and the “BRAIN Program” of 2013-2017, with a focus on funding basic research and technology development in neuroscience. Investments in the disease field focused on neurodegenerative diseases and dementia, depression, schizophrenia and autism. Since the 12th Five-Year Plan, China’s financial support in these areas has been greatly enhanced, and the investments in neurological diseases are much higher than those of mental diseases and neuroscience. NSFC has provided the largest financial support in the field of stroke and other cerebrovascular diseases. The development of basic neuroscience technology is primarily supported by the “973 Program” and the National key R&D programs.